Folic Acid
FDA-approved product (injectable, injection), marketed as Folic Acid, Folicet, Folvite and 1 more.
- Registered studies
- 50+
- Lab records
- 3
- Pathogens at ≥40%
- 4 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Acne
- Anemia
- Anemia (phenotype)
- Chronic kidney disease
- Chronic renal failure syndrome
- Depressive disorder
- Folate deficiency
- Iron deficiency anemia
- Major depressive disorder
- Osteoporosis
- Type 2 diabetes mellitus
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Folic acid and derivatives; Other diagnostic agents
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA43.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli87.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- K. pneumoniae47.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- M. tuberculosis50.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
- E. coli: measured active in 3 of 3 lab records
Show the 3 laboratory records, with sources
Loading records…
“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Folic Acid with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- UbrogepantExisting use: Migraine disorder53.8% AI-predicted activityagainst E. coli24 registered studies
- Caspofungin AcetateExisting use: Aspergillosis, Candidemia, Candidiasis and 1 more53.7% AI-predicted activityagainst E. coli50+ registered studies
- OdevixibatExisting use: Intrahepatic cholestasis53.7% AI-predicted activityagainst E. coli13 registered studies
- PosaconazoleExisting use: Aspergillosis, Candidiasis, Coccidioidomycosis and 2 more53.6% AI-predicted activityagainst E. coli50+ registered studies
- SiponimodExisting use: Multiple sclerosis53.6% AI-predicted activityagainst E. coli33 registered studies
- LonafarnibExisting use: Hutchinson-Gilford progeria syndrome, Laminopathies, Progeria53.6% AI-predicted activityagainst E. coli39 registered studies
- Brilliant Blue GExisting use: Disclosing Agent53.4% AI-predicted activityagainst E. coli10 registered studies
- AbarelixExisting use: Neoplasm53.4% AI-predicted activityagainst E. coli5 registered studies
- CyclosporineExisting use: Conjunctivitis, Corneal disease, Eye disease and 6 more53.3% AI-predicted activityagainst E. coli50+ registered studies
- Simeprevir SodiumExisting use: Chronic hepatitis C virus infection53.2% AI-predicted activityagainst E. coliNo documented evidence found
- Ergotamine TartrateExisting use: Headache, Migraine disorder53.1% AI-predicted activityagainst E. coli10 registered studies
- Maralixibat ChlorideExisting use: Alagille syndrome, Pruritus53.1% AI-predicted activityagainst E. coli5 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Iron Deficiency Anemia Can be an Indication for Treatment of Subclinical Hypothyroidism
NCT00535561 · start 2007-06
Registered record
- Registry ID
- NCT00535561
- Conditions
- Iron Deficiency Anemia; Subclinical Hypothyroidism
- Interventions
- Ferrous sulfate tablets 325 mg, po, TID; Ferrous sulfate plus levothyroxine
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2007-06
- Completion
- 2007-09
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionIron Deficiency Anemia; Subclinical HypothyroidismInterventionFerrous sulfate tablets 325 mg, po, TID; Ferrous sulfate plus levothyroxinePhasePhase 1Registry statusCompletedIron Supplementation in Schistosomiasis and Soil Transmitted Helminths Control Programmes in Zambia
NCT00276224 · start 2005-09
Registered record
- Registry ID
- NCT00276224
- Conditions
- Schistosomiasis; Helminthiases; Anaemia
- Interventions
- ferrous sulphate (drug)
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2005-09
- Completion
- 2006-04
- Enrolment
- 480
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSchistosomiasis; Helminthiases; AnaemiaInterventionferrous sulphate (drug)PhaseNot applicableRegistry statusCompletedStudy on Preventing Anemia in Children in Ghana
NCT00301054 · start 2005-06
Registered record
- Registry ID
- NCT00301054
- Conditions
- Anaemia in Children
- Interventions
- Ferrous sulphate; Sulphadoxine-Pyrimethamine
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2005-06
- Completion
- 2006-04
- Enrolment
- 872
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAnaemia in ChildrenInterventionFerrous sulphate; Sulphadoxine-PyrimethaminePhaseNot applicableRegistry statusCompletedPrenatal Multi-micronutrient Supplementation and Pregnancy Outcome
NCT00168688 · start 2001-01
Registered record
- Registry ID
- NCT00168688
- Conditions
- Pregnancy; Birth Weight
- Interventions
- multi micronutrient supplement; MN1; MN2
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2001-01
- Completion
- 2002-10
- Enrolment
- 2,100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPregnancy; Birth WeightInterventionmulti micronutrient supplement; MN1; MN2PhasePhase 1Registry statusCompletedIron Therapy in Colo-Rectal Neoplasm and Iron Deficiency Anemia: Intravenous Iron Sucrose Versus Oral Ferrous Sulphate.
NCT00199277
Registered record
- Registry ID
- NCT00199277
- Conditions
- Colorectal Neoplasm; Iron Deficiency Anemia
- Interventions
- i.v. iron sucrose; Oral iron
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Unknown
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- 150
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionColorectal Neoplasm; Iron Deficiency AnemiaInterventioni.v. iron sucrose; Oral ironPhasePhase 4Registry statusUnknown